Authors: R. Pudil Authors‘ workplace: I. interní kardioangiologická klinika LF UK a FN Hradec Králové Published in: Kardiol Rev Int Med 2017, 19(1): 30-33
The article presents a summary of essential diagnostic and therapeutic procedures in patients who are undergoing anti-cancer therapy, as recommended by the European Society of Cardiology. It deals with the basic clinical manifestations of cardiotoxicity: myocardial dysfunction and heart failure, coronary artery disease, valvular disease, arrhythmias and changes in QT interval, arterial hypertension, thromboembolism, stroke and peripheral artery disease, pulmonary hypertension and impairment pericardium.
Keywords: cardiotoxicity – cardio-oncology – heart failure – arrhythmias – guidelines
1. Zamorano JL, Lancellotti P, Rodriguez Muñoz D et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J 2016; 37(36): 2768 – 2801.
2. Elbl L. Pozdní následky kardiotoxicity. Kardiol Rev Int Med 2017; 19 (1): 22–29.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
